Intranasal Delivery of Temozolomide-Conjugated Gold Nanoparticles Functionalized with Anti-EphA3 for Glioblastoma Targeting
Glioblastoma multiforme (GBM) is a highly lethal and aggressive tumor of the brain that carries a poor prognosis. Temozolomide (TMZ) has been widely used as a first-line treatment for GBM. However, poor brain targeting, side effects, and drug resistance limit its application for the treatment of GBM...
Gespeichert in:
| Veröffentlicht in: | Molecular pharmaceutics Jg. 18; H. 3; S. 915 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
United States
01.03.2021
|
| Schlagworte: | |
| ISSN: | 1543-8392, 1543-8392 |
| Online-Zugang: | Weitere Angaben |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Glioblastoma multiforme (GBM) is a highly lethal and aggressive tumor of the brain that carries a poor prognosis. Temozolomide (TMZ) has been widely used as a first-line treatment for GBM. However, poor brain targeting, side effects, and drug resistance limit its application for the treatment of GBM. We designed a Temozolomide-conjugated gold nanoparticle functionalized with an antibody against the ephrin type-A receptor 3 (anti-EphA3-TMZ@GNPs) for targeted GBM therapy via intranasal administration. The system can bypass the blood-brain barrier and target active glioma cells to improve the glioma targeting of TMZ and enhance the treatment efficacy, while reducing the peripheral toxicity and drug resistance. The prepared anti-EphA3-TMZ@GNPs were 46.12 ± 2.0 nm and suitable for intranasal administration, which demonstrated high safety to the nasal mucosa in a toxicity assay. In vitro studies showed that anti-EphA3-TMZ@GNPs exhibited significantly enhanced cellular uptake and toxicity, and a higher cell apoptosis ratio has been seen compared with that of TMZ (54.9 and 14.1%, respectively) toward glioma cells (C6). The results from experiments on TMZ-resistant glioma cells (T98G) demonstrated that the IC
of anti-EphA3-TMZ@GNPs (64.06 ± 0.16 μM) was 18.5-fold lower than that of TMZ. In addition, Western blot analysis also revealed that anti-EphA3-TMZ@GNPs effectively down-modulated expression of O
-methylguanine-DNA methyltransferase and increased chemosensitivity of T98G to TMZ. The antiglioma efficacy in vivo was investigated in orthotopic glioma-bearing rats, and the results demonstrated that the anti-EphA3-TMZ@GNPs prolonged the median survival time to 42 days and increased tumor-cell apoptosis dramatically compared with TMZ. In conclusion, anti-EphA3-TMZ@GNPs could serve as an intranasal drug delivery system for efficacious treatment of GBM. |
|---|---|
| AbstractList | Glioblastoma multiforme (GBM) is a highly lethal and aggressive tumor of the brain that carries a poor prognosis. Temozolomide (TMZ) has been widely used as a first-line treatment for GBM. However, poor brain targeting, side effects, and drug resistance limit its application for the treatment of GBM. We designed a Temozolomide-conjugated gold nanoparticle functionalized with an antibody against the ephrin type-A receptor 3 (anti-EphA3-TMZ@GNPs) for targeted GBM therapy via intranasal administration. The system can bypass the blood-brain barrier and target active glioma cells to improve the glioma targeting of TMZ and enhance the treatment efficacy, while reducing the peripheral toxicity and drug resistance. The prepared anti-EphA3-TMZ@GNPs were 46.12 ± 2.0 nm and suitable for intranasal administration, which demonstrated high safety to the nasal mucosa in a toxicity assay. In vitro studies showed that anti-EphA3-TMZ@GNPs exhibited significantly enhanced cellular uptake and toxicity, and a higher cell apoptosis ratio has been seen compared with that of TMZ (54.9 and 14.1%, respectively) toward glioma cells (C6). The results from experiments on TMZ-resistant glioma cells (T98G) demonstrated that the IC
of anti-EphA3-TMZ@GNPs (64.06 ± 0.16 μM) was 18.5-fold lower than that of TMZ. In addition, Western blot analysis also revealed that anti-EphA3-TMZ@GNPs effectively down-modulated expression of O
-methylguanine-DNA methyltransferase and increased chemosensitivity of T98G to TMZ. The antiglioma efficacy in vivo was investigated in orthotopic glioma-bearing rats, and the results demonstrated that the anti-EphA3-TMZ@GNPs prolonged the median survival time to 42 days and increased tumor-cell apoptosis dramatically compared with TMZ. In conclusion, anti-EphA3-TMZ@GNPs could serve as an intranasal drug delivery system for efficacious treatment of GBM. Glioblastoma multiforme (GBM) is a highly lethal and aggressive tumor of the brain that carries a poor prognosis. Temozolomide (TMZ) has been widely used as a first-line treatment for GBM. However, poor brain targeting, side effects, and drug resistance limit its application for the treatment of GBM. We designed a Temozolomide-conjugated gold nanoparticle functionalized with an antibody against the ephrin type-A receptor 3 (anti-EphA3-TMZ@GNPs) for targeted GBM therapy via intranasal administration. The system can bypass the blood-brain barrier and target active glioma cells to improve the glioma targeting of TMZ and enhance the treatment efficacy, while reducing the peripheral toxicity and drug resistance. The prepared anti-EphA3-TMZ@GNPs were 46.12 ± 2.0 nm and suitable for intranasal administration, which demonstrated high safety to the nasal mucosa in a toxicity assay. In vitro studies showed that anti-EphA3-TMZ@GNPs exhibited significantly enhanced cellular uptake and toxicity, and a higher cell apoptosis ratio has been seen compared with that of TMZ (54.9 and 14.1%, respectively) toward glioma cells (C6). The results from experiments on TMZ-resistant glioma cells (T98G) demonstrated that the IC50 of anti-EphA3-TMZ@GNPs (64.06 ± 0.16 μM) was 18.5-fold lower than that of TMZ. In addition, Western blot analysis also revealed that anti-EphA3-TMZ@GNPs effectively down-modulated expression of O6-methylguanine-DNA methyltransferase and increased chemosensitivity of T98G to TMZ. The antiglioma efficacy in vivo was investigated in orthotopic glioma-bearing rats, and the results demonstrated that the anti-EphA3-TMZ@GNPs prolonged the median survival time to 42 days and increased tumor-cell apoptosis dramatically compared with TMZ. In conclusion, anti-EphA3-TMZ@GNPs could serve as an intranasal drug delivery system for efficacious treatment of GBM.Glioblastoma multiforme (GBM) is a highly lethal and aggressive tumor of the brain that carries a poor prognosis. Temozolomide (TMZ) has been widely used as a first-line treatment for GBM. However, poor brain targeting, side effects, and drug resistance limit its application for the treatment of GBM. We designed a Temozolomide-conjugated gold nanoparticle functionalized with an antibody against the ephrin type-A receptor 3 (anti-EphA3-TMZ@GNPs) for targeted GBM therapy via intranasal administration. The system can bypass the blood-brain barrier and target active glioma cells to improve the glioma targeting of TMZ and enhance the treatment efficacy, while reducing the peripheral toxicity and drug resistance. The prepared anti-EphA3-TMZ@GNPs were 46.12 ± 2.0 nm and suitable for intranasal administration, which demonstrated high safety to the nasal mucosa in a toxicity assay. In vitro studies showed that anti-EphA3-TMZ@GNPs exhibited significantly enhanced cellular uptake and toxicity, and a higher cell apoptosis ratio has been seen compared with that of TMZ (54.9 and 14.1%, respectively) toward glioma cells (C6). The results from experiments on TMZ-resistant glioma cells (T98G) demonstrated that the IC50 of anti-EphA3-TMZ@GNPs (64.06 ± 0.16 μM) was 18.5-fold lower than that of TMZ. In addition, Western blot analysis also revealed that anti-EphA3-TMZ@GNPs effectively down-modulated expression of O6-methylguanine-DNA methyltransferase and increased chemosensitivity of T98G to TMZ. The antiglioma efficacy in vivo was investigated in orthotopic glioma-bearing rats, and the results demonstrated that the anti-EphA3-TMZ@GNPs prolonged the median survival time to 42 days and increased tumor-cell apoptosis dramatically compared with TMZ. In conclusion, anti-EphA3-TMZ@GNPs could serve as an intranasal drug delivery system for efficacious treatment of GBM. |
| Author | Wang, Aiping Sha, Chunjie Li, Youxin Sun, Kaoxiang Lv, Yanan Wang, Liangxiao Yan, Xiuju Yu, Yawen Li, Nuannuan Tang, Shengnan |
| Author_xml | – sequence: 1 givenname: Liangxiao surname: Wang fullname: Wang, Liangxiao organization: School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Yantai 264005, P.R. China – sequence: 2 givenname: Shengnan surname: Tang fullname: Tang, Shengnan organization: School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Yantai 264005, P.R. China – sequence: 3 givenname: Yawen surname: Yu fullname: Yu, Yawen organization: School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Yantai 264005, P.R. China – sequence: 4 givenname: Yanan surname: Lv fullname: Lv, Yanan organization: School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Yantai 264005, P.R. China – sequence: 5 givenname: Aiping orcidid: 0000-0003-2165-6087 surname: Wang fullname: Wang, Aiping organization: School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Yantai 264005, P.R. China – sequence: 6 givenname: Xiuju surname: Yan fullname: Yan, Xiuju organization: School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Yantai 264005, P.R. China – sequence: 7 givenname: Nuannuan surname: Li fullname: Li, Nuannuan organization: School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Yantai 264005, P.R. China – sequence: 8 givenname: Chunjie surname: Sha fullname: Sha, Chunjie organization: State Key Laboratory of Long-Acting and Targeting Drug Delivery System, Luye Pharmaceutical Co., Ltd., Yantai 264003, P.R. China – sequence: 9 givenname: Kaoxiang surname: Sun fullname: Sun, Kaoxiang organization: School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Yantai 264005, P.R. China – sequence: 10 givenname: Youxin surname: Li fullname: Li, Youxin organization: School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Yantai 264005, P.R. China |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33417456$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkL1OwzAYRS0E4v8VkNlYUvyXpBmrAgUJwUD36ov9pTVy7GA7oMLLUwmQmO4djs5wTsi-Dx4JueRswpng16DTpA9u2EDsQeOYJ0wz1nC-R455qWQxlY3Y__ePyElKr4wJVQp5SI6kVLxWZXVMvh58juAhgaM36Ow7xi0NHV1iHz6DC701WMyDfx3XkNHQRXCGPoEPA8RstcNE70avsw0enP3cER82b-jMZ1vcDpuZpF2IdOFsaB2kHHqgS4hrzNavz8hBBy7h-e-ekpe72-X8vnh8XjzMZ48FyErmQkKppkapxpTTljXAdSealmsDXcfElDVlzUtsoUNhtGRgGDe1bitlUPBKnJKrH-sQw9uIKa96mzQ6Bx7DmFZC1VVZ7XrUO_TiFx3bHs1qiLaHuF395RLf8vt2DQ |
| CitedBy_id | crossref_primary_10_1016_j_fmre_2023_09_007 crossref_primary_10_3390_cells13020124 crossref_primary_10_3390_pharmaceutics16050669 crossref_primary_10_1039_D2BM01996E crossref_primary_10_3389_fonc_2024_1431636 crossref_primary_10_1016_j_cej_2025_164308 crossref_primary_10_3389_fnmol_2022_972615 crossref_primary_10_1016_j_colsurfa_2023_132286 crossref_primary_10_2174_1381612828666220603152918 crossref_primary_10_1002_adhm_202102610 crossref_primary_10_1002_mco2_70213 crossref_primary_10_1016_j_ejphar_2021_174588 crossref_primary_10_1186_s40478_025_02046_4 crossref_primary_10_1088_1748_605X_acf0ab crossref_primary_10_1007_s12274_023_6188_7 crossref_primary_10_2217_nnm_2021_0418 crossref_primary_10_1016_j_ijpharm_2024_124301 crossref_primary_10_1016_j_ejmech_2025_117288 crossref_primary_10_3390_cancers14215389 crossref_primary_10_3389_fbioe_2025_1601673 crossref_primary_10_3389_fonc_2025_1641752 crossref_primary_10_3389_fmolb_2022_1083645 crossref_primary_10_1016_j_jconrel_2024_05_044 crossref_primary_10_1134_S1061933X23700187 crossref_primary_10_1002_jbm_a_37281 crossref_primary_10_1002_ibra_12198 crossref_primary_10_1208_s12249_024_02946_z crossref_primary_10_1007_s11051_022_05524_1 crossref_primary_10_1016_j_jconrel_2023_04_022 crossref_primary_10_1007_s12088_024_01330_6 crossref_primary_10_3390_pharmaceutics13122014 crossref_primary_10_1016_j_colsurfb_2024_114285 crossref_primary_10_3390_neuroglia6030028 crossref_primary_10_1021_acsabm_4c01956 crossref_primary_10_1038_s41578_024_00684_z crossref_primary_10_1093_rpsppr_rqac003 crossref_primary_10_3389_fphar_2023_1081612 crossref_primary_10_1186_s12951_024_02526_0 crossref_primary_10_32604_or_2024_047278 crossref_primary_10_3389_fphar_2022_965789 crossref_primary_10_3390_biomedicines10071598 crossref_primary_10_1016_j_biopha_2023_115174 crossref_primary_10_1016_j_ijpharm_2025_125540 crossref_primary_10_3390_ph14070626 crossref_primary_10_1080_09205063_2024_2396721 crossref_primary_10_1016_j_jconrel_2022_08_024 crossref_primary_10_1016_j_ejpb_2021_08_011 crossref_primary_10_1016_j_jconrel_2023_12_054 crossref_primary_10_1016_j_nantod_2023_101961 crossref_primary_10_1016_j_mtbio_2025_101457 crossref_primary_10_1007_s13404_025_00357_x crossref_primary_10_1016_j_nxnano_2025_100137 crossref_primary_10_1016_j_xphs_2024_11_030 crossref_primary_10_2147_IJN_S378217 crossref_primary_10_1080_1061186X_2022_2119243 crossref_primary_10_1016_j_addr_2024_115481 crossref_primary_10_1007_s11051_023_05880_6 crossref_primary_10_1016_j_jddst_2023_104568 |
| ContentType | Journal Article |
| DBID | NPM 7X8 |
| DOI | 10.1021/acs.molpharmaceut.0c00911 |
| DatabaseName | PubMed MEDLINE - Academic |
| DatabaseTitle | PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1543-8392 |
| ExternalDocumentID | 33417456 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- -~X 123 4.4 53G 55A 5VS 7~N AABXI ABJNI ABMVS ABQRX ABUCX ACGFS ACS ADHLV AEESW AENEX AFEFF AHGAQ ALMA_UNASSIGNED_HOLDINGS AQSVZ BAANH CS3 CUPRZ DU5 EBS ED~ F5P GGK GNL H~9 IH9 JG~ NPM P2P RNS ROL UI2 VF5 VG9 W1F 7X8 ABBLG ABLBI |
| ID | FETCH-LOGICAL-a363t-3a548d449d58b09a1cf29b1cdaff028095715ebafe2dc30ad01d7cb64de2162 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 63 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000625450200014&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1543-8392 |
| IngestDate | Thu Oct 02 09:48:18 EDT 2025 Thu Jan 02 22:56:39 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | anti-EphA3 glioblastoma Temozolomide gold nanoparticles intranasal administration |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-a363t-3a548d449d58b09a1cf29b1cdaff028095715ebafe2dc30ad01d7cb64de2162 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0003-2165-6087 |
| PMID | 33417456 |
| PQID | 2476564177 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2476564177 pubmed_primary_33417456 |
| PublicationCentury | 2000 |
| PublicationDate | 2021-03-01 20210301 |
| PublicationDateYYYYMMDD | 2021-03-01 |
| PublicationDate_xml | – month: 03 year: 2021 text: 2021-03-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Molecular pharmaceutics |
| PublicationTitleAlternate | Mol Pharm |
| PublicationYear | 2021 |
| SSID | ssj0024523 |
| Score | 2.5390916 |
| Snippet | Glioblastoma multiforme (GBM) is a highly lethal and aggressive tumor of the brain that carries a poor prognosis. Temozolomide (TMZ) has been widely used as a... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 915 |
| Title | Intranasal Delivery of Temozolomide-Conjugated Gold Nanoparticles Functionalized with Anti-EphA3 for Glioblastoma Targeting |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/33417456 https://www.proquest.com/docview/2476564177 |
| Volume | 18 |
| WOSCitedRecordID | wos000625450200014&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1JS8QwFA5uiBf3fSGCeDLapGk7Ocmgjgo6DDiHuQ1pFqzMNKMdhdE_70tbmZMgeOkpLSF9ee9739sQOolkYBnACCKV4ITTQJM04imJTczTmAWKBmWh8EPSbjd6PdGpCbeiTqv80YmlotZOeY78gvEEoAenSXI5eiV-apSPrtYjNGbRfAhQxkt10mtMe-1F5Xg3QAkh8UBgER1XzQrohVTF-dD5ctaaOD4PFMANSn9HmqXFaa38d6-raLnGmrhZCccamjH5OjrtVJuZnOHutPaqOMOnuDNtYz3ZQF_3nvfNZQGfuDYDn78xwc7irhm6T1gzzLQhVy5_efdMnMa3bqAxKGvwwutkO9wCo1lxjdknrPCcL27m44zcjJ6bIQa8jG8HmUsBwY_dUOJumZYOxnQTPbVuuld3pB7VQGQYh2MSSvB8NOdCR400EJIqy0RKlZbW-uCtiBIamVRaw7QKA6kDqhOVxlwbRmO2heZyl5sdhEWkrI249yI59831fMAZXEhqhWCK2V10_HPkfbgIProhc-Pei_700HfRdvXf-qOqY0c_BFudAFTc-8Pb-2iJ-byVMs_sAM1bUAPmEC2oj3FWvB2VEgbPdufxG_Y13tA |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Intranasal+Delivery+of+Temozolomide-Conjugated+Gold+Nanoparticles+Functionalized+with+Anti-EphA3+for+Glioblastoma+Targeting&rft.jtitle=Molecular+pharmaceutics&rft.au=Wang%2C+Liangxiao&rft.au=Tang%2C+Shengnan&rft.au=Yu%2C+Yawen&rft.au=Lv%2C+Yanan&rft.date=2021-03-01&rft.issn=1543-8392&rft.eissn=1543-8392&rft.volume=18&rft.issue=3&rft.spage=915&rft_id=info:doi/10.1021%2Facs.molpharmaceut.0c00911&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1543-8392&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1543-8392&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1543-8392&client=summon |